News

DePuy Synthes Illustrates Future of Expanding VELYS™ Digital Surgery Platform at AAOS

27 August 2021

Both Hands-On and Virtual Reality Demonstrations with the VELYS™ Robotic-Assisted Solution, Now Commercially Available, to be Featured at Booth #2935

Smarter, More Personalized Technologies aimed at Delivering Data Insights and Remote Connectivity between Patients and their Care Teams will also be Featured

RAYNHAM, MA – August 26, 2021 – DePuy Synthes*, The Orthopaedics Company of Johnson & Johnson, today unveiled how it is further advancing its VELYS Digital Surgery Platform using digital technology, robotics, and data insights to improve patient care. During the American Academy of Orthopedic Surgeons (AAOS) annual meeting, the company is featuring its vision for the future of digital surgery with new technologies and enhancements designed to connect an ecosystem that starts pre-operatively and continues intra- and post-operatively.

Through its VELYS Digital Surgery Platform, DePuy Synthes is focused on delivering technology that can better inform clinical decisions across the full care continuum, starting with pre-operative patient selection through planning, surgical execution, and post-operative follow-up.

Among the recent advancements of the VELYS Digital Surgery Platform to be featured at AAOS is the VELYS Robotic-Assisted Solution for total knee arthroplasty, designed for use with the ATTUNE^® Total Knee System. Now commercially available in the U.S., the VELYS Robotic-Assisted Solution represents the next chapter in robotics designed around how surgeons plan, execute and perform total knee replacement surgery. Installations in hospitals and ASCs are underway, and more than 100 surgeries globally have been successfully performed to date with the system. The VELYS Robotic-Assisted Solution has recently additionally been cleared for use in Australia, New Zealand and Israel.

“Knowing its potential, our team had been eagerly awaiting availability of the VELYS Robotic-Assisted Solution. We were beyond excited to complete the first commercial total knee replacement procedure in the U.S. using this system in June,” said Dr. William Barrett**, orthopaedic surgeon at UW Valley Medical Center. “The VELYS Robotic-Assisted Solution is particularly advanced in its ability to help surgeons precisely plan surgery tailored to each patient’s unique anatomy, allowing the surgical team to more accurately visualize and predict joint stability with the ultimate goal of providing the best fit possible for enhanced patient outcomes.”

Demand for access to the VELYS Robotic-Assisted Solution has been significant with more than 1,000 surgeons and hospital staff receiving hands-on demonstrations to date. To meet the growing interest from hospitals and ASCs in the VELYS Robotic-Assisted Solution, DePuy Synthes has brought the technology on the road with the VELYS Mobile Lab as a means for doctors and hospital staff to gain hands-on experience with the innovative technology through surgical simulation and virtual reality training enabled by Johnson & Johnson Institute. The VELYS Mobile Lab makes its last stop along its cross-country journey at AAOS, where surgeons will have an opportunity this week to participate in demonstrations of the technology.

“We aim to bring disruptive innovations to the orthopaedics market through a connected and personalized digital platform,” said Sharrolyn Josse***, Worldwide President, VELYS Digital Surgery, DePuy Synthes. “With VELYS Digital Surgery we’re combining technology and data insights with an aim to increase decisiveness, enhance surgical precision and consistency, and make the overall experience more personalized for the patient and more efficient for all.”

At AAOS, DePuy Synthes will showcase other innovation highlights as part of its VELYS Digital Surgery Platform, including:

Introduction of VELYS Insights, an integrated clinical support solution that connects care teams to real-time, patient-specific data to help inform decisions pre-op and post-op. VELYS Insights includes two key capabilities: Care Coordination to help improve case management, surgery readiness and workflow efficiencies, and Patient Path Management designed to help care teams educate, support, communicate with, and remotely monitor patients using the VELYS Patient Path mobile app during their knee, hip, or shoulder replacement journey.

“VELYS Insights provides the opportunity to assess a patient pre-operatively and track the patient post-operatively in a user-friendly way that’s simply not available with current EMRs facilitating the process between patients, schedulers and physicians in real time,” said Dr. Michael L. Swank****, Orthopaedic Surgeon, Beacon Orthopaedics and Sports Medicine, Cincinnati, Ohio.

New Image Guidance capability for VELYS Hip Navigation, that is designed to offer precise analysis of implant selection and positioning through user friendly non-invasive navigation, pre-operative digital templating and case planning. It aims to help increase surgical reproducibility, drive OR efficiencies, and improve patient outcomes. DePuy Synthes is excited to introduce new image guidance for the ONETRIAL^® Analysis feature that will now enable intraoperative data driven decision making for patients positioned laterally, in addition to existing capabilities for the anterior approach technique.
With VELYS Digital Surgery, DePuy Synthes is building a platform of connected technologies powered by data insights before, during, and after surgery, and designed to elevate the orthopaedic experience for patients, surgeons, and care teams. We are taking steps to connect our technologies intraoperatively for real-time video data capture, transfer and display in customizable formats to meet our customer needs and provide a platform to support future development of data utilization capabilities.

DePuy Synthes plans to expand the VELYS Digital Surgery Platform beyond Joint Reconstruction across other surgical areas.

For more information on VELYS™ Digital Surgery, visit www.VELYSDigitalSurgery.com.

For more information about the ATTUNE^® Knee, visit www.ATTUNEevidence.com.

About Johnson & Johnson Medical Devices Companies
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.

About DePuy Synthes
DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS™ Digital Surgery portfolio, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide.

Building on our proud product innovation and legacy of industry firsts, we are reimagining the orthopaedic landscape with new advancements in medical technologies and digital surgery across the entire continuum of care to Keep People Moving today and tomorrow. For more information, visit www.depuysynthes.com.

* DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.
** Dr. William Barrett is a paid consultant for DePuy Synthes Joint Reconstruction.
*** Sharrolyn Josse is an employee of Medical Device Business Services, Inc.
**** Dr. Michael L. Swank is a paid consultant for DePuy Synthes Joint Reconstruction.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding DePuy Synthes products. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.